These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6659751)

  • 21. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
    Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
    Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
    Leyh H; Hall R; Mazeman E; Blumenstein BA
    Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The value of urine sediment cytomorphology in the ambulatory differential diagnosis of hematuria].
    Obroniecka I; Rojewska J; Wańkowicz Z
    Pol Merkur Lekarski; 1998 Nov; 5(29):285-7. PubMed ID: 10101502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of urine cytology testing and cystoscopy in women with irritative voiding symptoms.
    Sokol ER; Patel SR; Sung VW; Rardin CR; Weitzen S; Clemons JL; Myers DL
    Am J Obstet Gynecol; 2005 May; 192(5):1560-5. PubMed ID: 15902158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
    Karakiewicz PI; Benayoun S; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Marberger MJ; Shariat SF
    BJU Int; 2006 May; 97(5):997-1001. PubMed ID: 16542342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Patients with clinically unconfirmed positive urinary cytology --retrospective analysis of clinical courses].
    Kurimura Y; Takahashi A; Hirobe M; Kunishima Y; Masumori N; Matsukawa M; Ito N; Tsukamoto T
    Hinyokika Kiyo; 2007 Jul; 53(7):455-8. PubMed ID: 17702177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of urinary bladder cancer antigen and urine cytology in the diagnosis of bladder cancer.
    Shoshtari MA; Soleimani M; Moslemi M
    Urol J; 2005; 2(3):137-40. PubMed ID: 17602416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer.
    Wiener HG; Vooijs GP; van't Hof-Grootenboer B
    Acta Cytol; 1993; 37(2):163-9. PubMed ID: 8465635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer.
    Dalbagni G; Han W; Zhang ZF; Cordon-Cardo C; Saigo P; Fair WR; Herr H; Kim N; Moore MA
    Clin Cancer Res; 1997 Sep; 3(9):1593-8. PubMed ID: 9815848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic adenoma identified on urine cytology using PAX-2 immunostaining.
    Herlitz LC; Tong GX; Hamele-Bena D; Greenebaum E
    Diagn Cytopathol; 2008 Jan; 36(1):47-9. PubMed ID: 18064687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
    Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
    Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The significance of urine cytology three consecutive days after transurethral resection as a predictor of superficial bladder cancer recurrence].
    Yumura Y; Takase K; Kato Y; Hamano A; Mikata K; Ogo Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Mar; 50(3):171-6. PubMed ID: 15148768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
    Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
    Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
    Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
    Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.